| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Purpose: To investigate the cytoprotective effect of astaxanthin (ASX) on retinal ganglion cell (RGC) degeneration using a normal tension glaucoma (NTG) mouse model which lacks glutamate/aspartate transporter (GLAST) in Muller cells.
Methods: Three-week old GLAST+/- mice were given intraperitoneal injection of ASX (60, 30, and 10 mg/kg/day, respectively) or vehicle alone, and the wide type (WT) mice were given vehicle alone for 14 days, respectively. At the 5th week, the number of RGC 4-hydroxy-2-nonenal (HNE) in retinas was analyzed with Western blotting. and NF-ｋB was measured using an EIA assay kit. Results and Conclusion: The number of RGC of GLAST+/- mice significantly decreased, as compared to that of WT mice. However, RGC loss was suppressed by administration of ASX at a dose dependent manner. Following ASX administration, HNE was significantly down-regulated, but NF-ｋB was steady. Our data suggest that ASX may be applicable for NTG as a promising therapeutics.
|
